The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
Improvements in positive symptoms of schizophrenia include hallucinations and delusions.
Improvements in negative symptoms of schizophrenia include affective flattening, alogia, anhedonia, motivation, and asociality.
Improvements in cognitive dysfunction include attention/vigilance, reasoning, problem-solving, processing speed, working memory, verbal learning and memory, visual learning and memory, and social cognition.
Extrapyramidal side effects (EPS) include dystonia, Parkinsonism, akathisia, and tardive dyskinesia.
Side effects related to postsynaptic dopamine receptor blockade include EPS, prolactin elevation, and sexual side effects.
Anticholinergic side effects include constipation and dyspepsia.
Cardiometabolic side effects include weight gain, dyslipidemia, and hyperglycemia.1
Read more about Novel and Emerging Pharmacologic Treatments for Schizophrenia
Related content
Continuous maintenance therapy is associated with a lower risk of relapse than intermittent treatment, supporting ongoing treatment strategies in schizophrenia and related psychotic disorders.
Treatment response tends to be higher during a first episode than during subsequent episodes, emphasizing the importance of early intervention and effective management.
Negative symptoms are a core feature of schizophrenia and can have a profound impact on functioning, social relationships, and quality of life.